Results 71 to 80 of about 110,931 (189)

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data

Tumor Biology, 2017
To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy.
Meidan Liu, Yayuan Zheng, Zuguang Chen, Yumiao Qiu, Zhanchun Pan, Zitao Cai, Yapeng Shi, Junfen Cheng, Weimin Yao   +8 more
doaj   +1 more source

Storage stability of bevacizumab in polycarbonate and polypropylene syringes [PDF]

, 2015
Purpose To compare and examine the storage stability of compounded bevacizumab in polycarbonate (PC) and polypropylene (PP) syringes over a 6-month period.
Froome, Andrew, Khaw, Peng Tee, Brocchini, Steve, Sharma, Garima, Khalili, Hanieh   +4 more
core  

Technical Feasibility of Laparoscopic Total Mesorectal Excision for Patients with Low Rectal Cancer after Concurrent Radiation and Chemotherapy with Bevacizumab Plus Folfox

, 2012
This study aimed to evaluate the technical feasibility of laparoscopic total mesorectal excision TME for the treatment of low rectal cancer after concurrent chemoradiation therapy CCRT with bevacizumab and FOLFOX.
梁金銅;賴鴻?, Liang, Jin-Tung; Lai, Hong-Shiee; Cheng, Kuo-Wei   +1 more
core   +1 more source

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy

Physics and Imaging in Radiation Oncology, 2018
Stereotactic body radiotherapy (SBRT) and bevacizumab are used in the treatment of colorectal liver metastases. This study prospectively evaluated changes in perfusion of liver metastases in seven patients treated with both bevacizumab and SBRT ...
Jay S. Detsky, Laurent Milot, Yoo-Joung Ko, Pablo Munoz-Schuffenegger, William Chu, Gregory Czarnota, Hans T. Chung   +6 more
doaj   +1 more source

Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

, 2010
Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced /metastatic hepatocellular carcinoma (HCC).
徐志宏;許駿;陳培哲;林宗哲;趙祖怡;鄭安理, P-J Chen, C Hsu, H C Toh, A-L Cheng, Z-Z Lin, L-T Hsiao, HSU, CHIH-HUNG;HSU, CHIUN;CHEN, PEI-JER;LIN, ZONG-ZHE;CHAO, TSU-YI;CHENG, ANN-LII, C-H Hsu, T-S Yang, R J Epstein, T-Y Chao   +11 more
core   +1 more source

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study

, 2016
Objective To evaluate the timing and pattern of relapse, and duration of response to second line chemotherapy in advanced ovarian cancer (AOC) patients treated with first line carboplatin-paclitaxel chemotherapy with or without bevacizumab.
Petrillo, Marco, Scambia, Giovanni, Salutari, Vanda, Fagotti, Anna, Amadio, Giulia, Paris, Ida   +5 more
core   +1 more source

Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

, 2016
Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer.
Padula, Gilbert Da, Morganti, Alessio Giuseppe, Cilla, Savino, Picardi, Vincenzo, Caravatta, Luciana, Valentini, Vincenzo, Macchia, Gabriella, Autorino, Rosa, Cellini, Francesco, Buwenge, Milly, Balducci, Mario, Mignogna, Samantha, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Lullo, Liberato DI, Deodato, Francesco   +15 more
core   +1 more source

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Cancer Reports
Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to ...
Kunpeng Fang, Jie Wang, Jianyong Yuan, Chengjun Sui, Jiajun Zhi, Yong Xia, Minmin Sun   +6 more
doaj   +1 more source

Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema

Central Asian Journal of Medical Sciences, 2016
Objectives: To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME). Methods: One hundred
Anaraa Toishubai, Uranchimeg Davaatseren, Baasankhuu Jamyanjav, Sun Taek Lim, Bulgan Tuvaan, Munkhzaya Tsengenbayar, Munkhkhishig Batbileg, Oyunzaya Luvsantseren, Urangua Jamyansuren, Munkhsaikhan Munkhkhuyag, Unudeleg Bayaraa, Khudrenchuluun Nanjid, Yerkyebulan Muktar, Unurtsetseg Chandaga, Chimedsuren Ochir   +14 more
doaj   +1 more source

Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model

Scientific Reports
Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant genetic disorder characterized by the development of cranial and peripheral nerve schwannomas, including bilateral vestibular schwannomas which are associated with ...
Jennifer L. Spiegel, Alessandro De Maio, Manita V. Patel, Omer J. Ungar, Carolyn Lai, Tra Truong, Yumai Situ, D. Wade Clapp, Simon J. Conway, Joseph M. Chen, Vincent Y. W. Lin, Kullervo Hynynen, Meaghan A. O’Reilly, Trung N. Le   +13 more
doaj   +1 more source